Highlights of weekly biotech stock moves

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) gained $3.69 (23%) to $19.65 last week after FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 13-2 that efficacy and safety data for lomitapide support approval to treat homozygous familial hypercholesterolemia (hoFH).

The biotech agreed to conduct a long-term postmarketing observational study of lomitapide that would monitor drug effects on liver enzymes and hepatotoxicity in 300 patients, which represents almost half of the estimated 750 hoFH patients in the U.S. and EU. FDA recommended eight years of follow-up for the trial...